jaktinib

Evidence outlook · registrational

Atopic Dermatitis: registrational readout pending

Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.

NCT04539639: The study was randomized, double-blind, and placebo-controlled with 166 participants, and it used a validated clinical disease-activity measure as its primary endpoint. However, the primary comparison cannot be judged because results have not been posted, so the evidence remains limited despite the strong trial design.